Medicaid cuts in Trump’s megabill will hit some drugmakers

A version of this article was first published in the CNBC’s healthy return bulletin, which brought the latest health news directly to your box. Subscribe here To get future prints.

We returned with President Donald from the holiday weekend Trump’s “Big Beuthiful” bill has officially signed the law.

The turning point tax reduction and expenditure package contains more than $ 1 trillion in Medicaid, which will leave millions of vulnerable Americans without health insurance and threaten hospitals and centers that provide care for them. Although reducing health care expenditures will be large human costs, it will also affect the pharmaceutical industry.

Medicaid constitutes some of the income of many drug producers in the United States and a smaller part of its total income worldwide. According to the Monday note of Leerink Partners Analyst David Risinger, Medicaid is also reimbursing for drugs lower than other programs such as Medicare or commercial insurance.

This is due to a program that requires a large extent from a program that requires drug manufacturers to provide reduction to states in exchange for medicaid, which causes lower net medication prices.

Nevertheless, Risinger said for drug producers, “future loss of income is a marginal negative.”

He also said that some companies have been exposed to the Medicaid market than others based on previous company comments and internal estimates of the company.

TEPE DRUGS And Gilead Risinger rely on Medicaid more than other large cover pharmaceutical companies. According to the note, Medicaid constitutes 25% of Vertex’s US revenue and 22% of Gilead’s local sales.

Peak described At a conference held in June, it accounts for 23% of the sales of Medicaid, the company’s main income drivers, cystic fibrosis drugs. These tracks: Half of all children and one third of all adults According to the Cystic Fibrosis Foundation, this genetic situation relys on Medicaid to provide a healthy life to provide treatments and care.

Medicaid also plays a major role in the populations that receive inadequate service, which is a fundamental focus, especially for Gilead, especially in HIV prevention and treatment. For example, the company’s HIV treatment pill Biktarvy ranked second in 2022 in terms of total Medicaid drug expenditures in 2022, according to a note of Jeffes analysts in March, and was still one of the most widely used drugs in 2024.

Nevertheless, analysts said Gilead’s hit business would probably be “manageable” from Medicaid cuts. The note was based on estimates from a previous version of the invoice.

Commercial insurance companies also provide most of the coverage area for HIV prevention and ongoing treatment, while Medicaid plays a smaller, but still important, role.

Medicaid represents 12% Johnson & JohnsonDomestic sales (except for medical device work) and 12% Novo NordiskUS income. Among the major pharmaceutical companies, Bristol Myers Squibb And Pfizer It had the lowest exposure, only 4% of US revenues come from Medicaid.

Risinger said he represents 15% of Medicaid RocheUS income. However, Roche said on Tuesday that the market constitutes only less than 10% of sales in the country.

Risinger said that the Medicaid cuts will not take place until November 2026 midterm exams, so any financial impact for drug producers will essentially begin in 2027.

There is another significant gain for Trump’s invoice to take into account drug producers: a provision that will exempt more medication than the Medicare drug price negotiations of the Inflation Reduction Law.

We will continue to monitor the impact of the legislation on the sector, so continue watching us.

Feel free to send any clues, suggestions, story ideas and data to Annika. Annikakim.constantino@nbcuni.com.

We are in half of 2025, so we have some new digital health financing data to examine. Even in a variable macroeconomic and policy environment, the sector saw a “strong momentum”. A new report From Rock Health.

In the report, digital health companies in the United States received $ 6.4 billion in the first half of the year between 6 billion dollars in the same period last year and in the first half of 2023 in the first half of 2023. Since 2023, the sector has provided a $ 3.4 billion attempt finance in the second quarter up to $ 2.6 billion per quarter.

Initiatives, which use artificial intelligence as a basic part of their products, increased 62% of the entire digital health venture financing in the first half of the year, when AI companies first captured the majority of new capital. These businesses drew an average of $ 34.4 million per tour.

“Digital health proves that it is more than stable and flexible, the sector is entering a new stage of traction and influence in which AI plays a Linhpin role.” He said.

However, at the end of the financing, the census of the agreement decreased slightly. In the report, digital health companies closed 245 agreements in the first half of the year, while in the same period of the previous year, they closed 273. Nevertheless, the rise of over $ 100 million is increasing. In the first half of the year, there were 11 megadeal at the speed of passing 17 megadeals in the entire 2024.

This year there is also a merger and purchasing activity in digital health. The sector closed the 107 m & A agreement in the first half of 2025, which may overcome a total of 121 m & A agreement closed in 2024.

And many digital health investors have been relieved of the relief, Hingge Health and Oda Health jumped and launched in public markets. Rock Health said that these outputs were undeniables that “2025’s breaking moments so far”.

“This public market outlets have provided investors a drought, challenging public market performances and recent salvation after a number of buyers.” He said.

Read the entire report Here.

Feel free to send any clues, suggestions, story ideas and data to Ashley at Ashley.capoot@nbcuni.com.